If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Sector movers: Telecoms in demand

Thu, 28th Oct 2010 11:27
Mobile Telecommunications has had a good reception Thursday, with heavyweight Vodafone, ably supported by Inmarsat and minnow Mobile Streams.Big gun AstraZeneca is dragging down Pharmaceuticals & Biotechnology. Earlier today it reported a bigger than expected 4% drop in third quarter sales to $7.9bn. Core earnings per share fell 10% to $1.50.Panmure Gordon thinks gross margin will be seen as the biggest concern, as it fell by 3.9 percentage points from a year earlier to 80.7%, but its still rates the shares a 'buy'.Top performing sectors so far todayAlternative Energy 2,925.99 +6.02%Mobile Telecommunications 3,918.41 +2.91%Technology Hardware & Equipment 574.00 +2.14%Industrial Metals & Mining 7,479.70 +1.80%Aerospace and Defence 3,405.65 +1.38%Bottom performing sectors so far todayPharmaceuticals & Biotechnology 8,980.33 -1.65%Automobiles & Parts 4,098.63 -1.52%Industrial Engineering 6,080.37 -0.99%Chemicals 6,456.45 -0.71%Forestry & Paper 5,611.88 -0.67% Astrazeneca Vodafone

Shares in this article

Related News

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears
10 hours ago

LONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears

(Alliance News) - European stocks soared on Thursday as weaker than expected US jobs figures dampened market worries of a near-term interest rate hike...

Market News BAE Systems + 15 more shares
Hutchmed drug approved in China for advanced gastric cancer
13 hours ago

Hutchmed drug approved in China for advanced gastric cancer

(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer wi...

Pharmaceuticals Hutchmed + 1 more share
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
16 hours ago

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

July 2 (Reuters) - AstraZeneca ​has entered into a deal worth up to $1.77 billion ​with β€ŒCSPC Pharmaceutical Group to discover and develop experimenta...